menu
    • menu
    [{"orgOrder":0,"company":"Pyramid Bio","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"PBI-200","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyramid Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pyramid Bio \/ Caris","highestDevelopmentStatusID":"7","companyTruncated":"Pyramid Bio \/ Caris"},{"orgOrder":0,"company":"Pyramid Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PBI-200","moa":"TRK kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyramid Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pyramid Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Pyramid Bio \/ Not Applicable"},{"orgOrder":0,"company":"Pyramid Bio","sponsor":"GeneQuantum Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"GQ1010","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pyramid Bio","amount2":1.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Pyramid Bio \/ GeneQuantum Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Pyramid Bio \/ GeneQuantum Healthcare"}]

    Find Clinical Drug Pipeline Developments & Deals by Pyramid Bio

    Menu

    Pyramid Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pyramid Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Pyramid Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GQ1010

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : GeneQuantum Healthcare

                            Deal Size : $1,020.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pyramid Biosciences Expands Oncology Pipeline with In-Licensing of GQ1010, a Potential Best-in-class TROP2 Tar...

                            Details : Under the terms of the agreement, Pyramid Biosciences will develop and commercialize GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting TROP2, worldwide except for Greater China, using GeneQuantum's proprietary technology.

                            Brand Name : GQ1010

                            Molecule Type : Large molecule

                            Upfront Cash : $20.0 million

                            April 13, 2023

                            Lead Product(s) : GQ1010

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : GeneQuantum Healthcare

                            Deal Size : $1,020.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pyramid Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Pyramid Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PBI-200

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDA

                            Details : PBI-200 is an oral, highly potent, and selective inhibitor of TRK kinase that is currently in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases.

                            Brand Name : PBI-200

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 06, 2022

                            Lead Product(s) : PBI-200

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pyramid Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Pyramid Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PBI-200

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Caris Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Pyramid Biosciences and Caris Life Sciences Announce MI Trials Collaboration for Clinical Trial Matching in Su...

                            Details : Molecular Intelligence Trials (MI Trials) collaboration will enhance identification of patients with NTRK fusion-positive solid tumors, including primary and metastatic CNS tumors potentially eligible for enrollment in the ongoing PBI-200-101 Phase 1/2 c...

                            Brand Name : PBI-200

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 10, 2022

                            Lead Product(s) : PBI-200

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Caris Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth